Drug screening in the immediate term will be best accomplished by early use of primary cells in which the target of the screen is a network of proteins measured in populations of single cells.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
High-throughput screening unveils nitazoxanide as a potent PRRSV inhibitor by targeting NMRAL1
Nature Communications Open Access 06 June 2024
-
FORTIS: a live-cell assay to monitor AMPA receptors using pH-sensitive fluorescence tags
Translational Psychiatry Open Access 27 May 2021
-
Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution
Scientific Reports Open Access 03 December 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lou, K. & de Rond, M. Nat. Rev. Drug Discov. 5, 451–452 (2006).
Mervis, J. Science 309, 726 (2005).
Wood, A.J.J. N. Engl. J. Med. 355, 618–623 (2006).
Krumholz, H., Ross, J., Presler, A. & Egilman, D. Br.Med. J. 334, 120–123 (20072007).
Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Adv. Drug Deliv. Rev. 46, 3–26 (2001).
Irish, J.M. et al. Cell 118, 217–228 (2004).
Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D.A. & Nolan, G.P. Science 308, 523–529 (2005).
Perez, O.D. & Nolan, G.P. Nat. Biotechnol. 20, 155–162 (2002).
Krutzik, P.O. & Nolan, G.P. Cytometry A 55, 61–70 (2003).
Krutzik, P.O. & Nolan, G.P. Nat. Methods 3, 361–368 (2006).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
G.P.N. is the chair of the science advisory board of a molecular diagnostics company and a holder of equity in this company. G.P.N. also advises (i) a large pharmaceutical company that is creating molecular diagnostics and (ii) a drug screening company on screening approaches.
Rights and permissions
About this article
Cite this article
Nolan, G. What's wrong with drug screening today. Nat Chem Biol 3, 187–191 (2007). https://doi.org/10.1038/nchembio0407-187
Issue Date:
DOI: https://doi.org/10.1038/nchembio0407-187
This article is cited by
-
High-throughput screening unveils nitazoxanide as a potent PRRSV inhibitor by targeting NMRAL1
Nature Communications (2024)
-
FORTIS: a live-cell assay to monitor AMPA receptors using pH-sensitive fluorescence tags
Translational Psychiatry (2021)
-
Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution
Scientific Reports (2020)
-
Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia
Scientific Reports (2019)
-
Drug Screening of Human GBM Spheroids in Brain Cancer Chip
Scientific Reports (2018)